Navigation Links
Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
Date:8/15/2012

Researchers at Moffitt Cancer Center, working with colleagues in Sweden, the Netherlands and Puerto Rico, have validated a radiosensitivity molecular signature that can lead to better radiation therapy decisions for treating patients with breast cancer.

The results appeared in a recent issue of Clinical Cancer Research, a publication of the American Association for Cancer Research.

The study examined patients with breast cancer who had been treated with radiation therapy and demonstrated that a radiosensitivity molecular signature (RSI) could predict clinical outcomes exclusively in patients treated with radiation therapy. The radiosensitivity molecular signature (RSI) used by the research team had previously been tested and validated for rectal, esophageal, and head and neck cancers. The technology, which identifies radiosensitivity and radioresistance, opens the door to biologically guided radiation therapy and offers the potential for better outcomes.

"Developing a radiosensitivity predictive assay has been a goal of radiation biology for decades," said Javier F. Torres-Roca, M.D., member of the Experimental Therapeutics program at Moffitt. "This effort supports the emphasis on personalized medicine, where the goal is to use molecular signatures to guide therapeutic decisions."

According to Torres-Roca, approximately 60 percent of all cancer patients receive radiation therapy during their treatment. Yet until now, no molecular diagnostic or biomarker of radiosensitivity had been developed to predict its benefit.

The radiosensitivity molecular signature was developed based on gene expression for 10 specific genes and a linear regression algorithm. RSI was developed in 48 cancer cell lines using a systems-biology strategy focused on identifying biomarkers for cellular radiosensitivity.

This study validated RSI's benefit when researchers found that radiosensitive breast cancer patients had an improved five-year, relapse-free survival when compared to radioresistant patients.

"This study validated RSI in 503 patients in two independent data sets," Torres-Roca said. "We have validated RSI in five independent cohorts totaling 621 patients, so this latest validation study, to the best of our knowledge, makes this technology the most extensively validated molecular signature in radiation oncology."

The successful transition from applying the technology to cell lines to patient application also suggests that the biological basis of cellular radiosensitivity is conserved between cell lines and patients and also across epithelial tumors, Torres-Roca said.

"We propose that RSI is a predictive biomarker of radiation therapy therapeutic benefit for patients with breast cancer," Torres-Roca said. "This novel biomarker provides an opportunity to integrate individual tumor biology with clinical decision-making in radiation oncology."


'/>"/>
Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
2. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
3. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
4. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
5. Moffitt Cancer Center study validates activity of rare genetic variant in glioma
6. Moffitt researchers find cutaneous human papillomavirus infection a risk factor for skin cancer
7. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
8. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
9. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
10. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
11. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Worth, TX (PRWEB) , ... October 13, 2017 ... ... financial planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, ... young boy fighting to overcome a rare and deadly chromosome abnormality. , After ...
(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... ORLANDO, Fla. , Oct. 2, 2017  AllianceRx ... services company formed by Walgreens and pharmacy benefit manager ... of its new brand, which included the unveiling of ... Fla. , as well as at a few ... introduces the new brand to patients, some of whom ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
Breaking Medicine Technology: